398 related articles for article (PubMed ID: 28398261)
1. Novel Proteasome Inhibitors and Histone Deacetylase Inhibitors: Progress in Myeloma Therapeutics.
Chhabra S
Pharmaceuticals (Basel); 2017 Apr; 10(2):. PubMed ID: 28398261
[TBL] [Abstract][Full Text] [Related]
2. Ricolinostat (ACY-1215) induced inhibition of aggresome formation accelerates carfilzomib-induced multiple myeloma cell death.
Mishima Y; Santo L; Eda H; Cirstea D; Nemani N; Yee AJ; O'Donnell E; Selig MK; Quayle SN; Arastu-Kapur S; Kirk C; Boise LH; Jones SS; Raje N
Br J Haematol; 2015 May; 169(3):423-34. PubMed ID: 25709080
[TBL] [Abstract][Full Text] [Related]
3. Ricolinostat, the First Selective Histone Deacetylase 6 Inhibitor, in Combination with Bortezomib and Dexamethasone for Relapsed or Refractory Multiple Myeloma.
Vogl DT; Raje N; Jagannath S; Richardson P; Hari P; Orlowski R; Supko JG; Tamang D; Yang M; Jones SS; Wheeler C; Markelewicz RJ; Lonial S
Clin Cancer Res; 2017 Jul; 23(13):3307-3315. PubMed ID: 28053023
[No Abstract] [Full Text] [Related]
4. Expression of histone deacetylase (HDAC) family members in bortezomib-refractory multiple myeloma and modulation by panobinostat.
Cheng T; Kiser K; Grasse L; Iles L; Bartholomeusz G; Samaniego F; Orlowski RZ; Chandra J
Cancer Drug Resist; 2021; 4(4):888-902. PubMed ID: 34888496
[TBL] [Abstract][Full Text] [Related]
5. Small-molecule inhibition of proteasome and aggresome function induces synergistic antitumor activity in multiple myeloma.
Hideshima T; Bradner JE; Wong J; Chauhan D; Richardson P; Schreiber SL; Anderson KC
Proc Natl Acad Sci U S A; 2005 Jun; 102(24):8567-72. PubMed ID: 15937109
[TBL] [Abstract][Full Text] [Related]
6. The proteasome and proteasome inhibitors in multiple myeloma.
Gandolfi S; Laubach JP; Hideshima T; Chauhan D; Anderson KC; Richardson PG
Cancer Metastasis Rev; 2017 Dec; 36(4):561-584. PubMed ID: 29196868
[TBL] [Abstract][Full Text] [Related]
7. Overcoming inherent resistance to histone deacetylase inhibitors in multiple myeloma cells by targeting pathways integral to the actin cytoskeleton.
Mithraprabhu S; Khong T; Spencer A
Cell Death Dis; 2014 Mar; 5(3):e1134. PubMed ID: 24651437
[TBL] [Abstract][Full Text] [Related]
8. Exploring the role of histone deacetylase and histone deacetylase inhibitors in the context of multiple myeloma: mechanisms, therapeutic implications, and future perspectives.
Pu J; Liu T; Wang X; Sharma A; Schmidt-Wolf IGH; Jiang L; Hou J
Exp Hematol Oncol; 2024 Apr; 13(1):45. PubMed ID: 38654286
[TBL] [Abstract][Full Text] [Related]
9. Deacetylase inhibitors as a novel modality in the treatment of multiple myeloma.
Richardson PG; Moreau P; Laubach JP; Maglio ME; Lonial S; San-Miguel J
Pharmacol Res; 2017 Mar; 117():185-191. PubMed ID: 27884726
[TBL] [Abstract][Full Text] [Related]
10. Targeting the integrated networks of aggresome formation, proteasome, and autophagy potentiates ER stress‑mediated cell death in multiple myeloma cells.
Moriya S; Komatsu S; Yamasaki K; Kawai Y; Kokuba H; Hirota A; Che XF; Inazu M; Gotoh A; Hiramoto M; Miyazawa K
Int J Oncol; 2015 Feb; 46(2):474-86. PubMed ID: 25422130
[TBL] [Abstract][Full Text] [Related]
11. Old and new generation proteasome inhibitors in multiple myeloma.
Montefusco V; Mussetti A; Salas MQ; Martinelli G; Cerchione C
Panminerva Med; 2020 Dec; 62(4):193-206. PubMed ID: 32957744
[TBL] [Abstract][Full Text] [Related]
12. The novel orally active proteasome inhibitor K-7174 exerts anti-myeloma activity in vitro and in vivo by down-regulating the expression of class I histone deacetylases.
Kikuchi J; Yamada S; Koyama D; Wada T; Nobuyoshi M; Izumi T; Akutsu M; Kano Y; Furukawa Y
J Biol Chem; 2013 Aug; 288(35):25593-25602. PubMed ID: 23878197
[TBL] [Abstract][Full Text] [Related]
13. Discovery of the First-in-Class Dual Histone Deacetylase-Proteasome Inhibitor.
Bhatia S; Krieger V; Groll M; Osko JD; Reßing N; Ahlert H; Borkhardt A; Kurz T; Christianson DW; Hauer J; Hansen FK
J Med Chem; 2018 Nov; 61(22):10299-10309. PubMed ID: 30365892
[TBL] [Abstract][Full Text] [Related]
14. Proteasome inhibitors - molecular basis and current perspectives in multiple myeloma.
Kubiczkova L; Pour L; Sedlarikova L; Hajek R; Sevcikova S
J Cell Mol Med; 2014 Jun; 18(6):947-61. PubMed ID: 24712303
[TBL] [Abstract][Full Text] [Related]
15. The power of proteasome inhibition in multiple myeloma.
Guerrero-Garcia TA; Gandolfi S; Laubach JP; Hideshima T; Chauhan D; Mitsiades C; Anderson KC; Richardson PG
Expert Rev Proteomics; 2018 Dec; 15(12):1033-1052. PubMed ID: 30427223
[TBL] [Abstract][Full Text] [Related]
16. The mTOR inhibitor everolimus overcomes CXCR4-mediated resistance to histone deacetylase inhibitor panobinostat through inhibition of p21 and mitotic regulators.
Beider K; Bitner H; Voevoda-Dimenshtein V; Rosenberg E; Sirovsky Y; Magen H; Canaani J; Ostrovsky O; Shilo N; Shimoni A; Abraham M; Weiss L; Milyavsky M; Peled A; Nagler A
Biochem Pharmacol; 2019 Oct; 168():412-428. PubMed ID: 31325448
[TBL] [Abstract][Full Text] [Related]
17. Panobinostat From Bench to Bedside: Rethinking the Treatment Paradigm for Multiple Myeloma.
Berdeja JG; Laubach JP; Richter J; Stricker S; Spencer A; Richardson PG; Chari A
Clin Lymphoma Myeloma Leuk; 2021 Nov; 21(11):752-765. PubMed ID: 34340951
[TBL] [Abstract][Full Text] [Related]
18. Response of myeloma to the proteasome inhibitor bortezomib is correlated with the unfolded protein response regulator XBP-1.
Ling SC; Lau EK; Al-Shabeeb A; Nikolic A; Catalano A; Iland H; Horvath N; Ho PJ; Harrison S; Fleming S; Joshua DE; Allen JD
Haematologica; 2012 Jan; 97(1):64-72. PubMed ID: 21993678
[TBL] [Abstract][Full Text] [Related]
19. Carfilzomib and oprozomib synergize with histone deacetylase inhibitors in head and neck squamous cell carcinoma models of acquired resistance to proteasome inhibitors.
Zang Y; Kirk CJ; Johnson DE
Cancer Biol Ther; 2014 Sep; 15(9):1142-52. PubMed ID: 24915039
[TBL] [Abstract][Full Text] [Related]
20. The aggresome pathway as a target for therapy in hematologic malignancies.
Simms-Waldrip T; Rodriguez-Gonzalez A; Lin T; Ikeda AK; Fu C; Sakamoto KM
Mol Genet Metab; 2008 Jul; 94(3):283-6. PubMed ID: 18472289
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
